Helmholtz Diabetes Center
Helmholtz Institute for Metabolic, Obesity, and Vascular Research
The Helmholtz Institute for Metabolic, Obesity, and Vascular Research (Helmholtz-Institut für Metabolismus-, Adipositas- und Gefäßforschung, HI-MAG) in Leipzig investigates molecular mechanisms linking adipose tissue dysfunction to metabolic and vascular diseases.
The Helmholtz Institute for Metabolic, Obesity, and Vascular Research (Helmholtz-Institut für Metabolismus-, Adipositas- und Gefäßforschung, HI-MAG) in Leipzig investigates molecular mechanisms linking adipose tissue dysfunction to metabolic and vascular diseases.
Take a look at our Metabolic Chambers:
Bioinformatics Core Unit
Our institute is supported by an expert group of bioinformaticians. Learn more about the people and their projects here.
Clinical Trial Unit
Our clinical studies are part of our Clinicial Trial Unit and carried out in cooperation with the Leipzig Medical Center. For further information, please click here.
Director of the Helmholtz Institute for Metabolic, Obesity and Vascular Research and Head of Research Group Clinical Obesity Research, HI-MAG
View profile
HI-MAG Institute's Manager
Group Leader of Adipose Tissue Microarchitecture and Metabolism, HI-MAG
View profilePublications of HI-MAG
Düsing, S. ; Wittig, T. ; Winther, B. ; Schmidt, A. ; Scheinert, D. ; Steiner, S.
Mid-term results of orbital atherectomy in heavily calcified lesions above and below the knee.Gil Lozano, M. ; Simoes Fernandez, E. ; Wu, M. ; Wiedemann, T. ; Kwon, Y. ; Sekar, R. ; Morigny, P. ; Troullinaki, M. ; Merl-Pham, J. ; Buettner, M. ; Feuchtinger, A. ; Jouffe, C. ; Maida, A. ; Hass, D, ; Samaga, D. ; Wolff, G. ; Machado, J. ; Giroud, M. ; Klepac, K. ; Cummins, C.L. ; Rios Garcia, M. ; Weber, P. ; Zeigerer, A. ; Uhlenhaut, N.H. ; Szendroedi, J. ; Blüher, M. ; Herzig, S.
Combinatorial targeting of the miR-379/miR-410 cluster normalizes glucose and lipid homeostasis in male models of diabetes and obesity.Kokot, K.E. ; Reichardt, S. ; Menedo, C. ; Erbe, S. ; Kneuer, J.M. ; Palm, K.C. ; Hoba, J. ; Andritschke, M. ; Katzmann, M. ; Reuser, A. ; Scheidt, M.v. ; Mokrý, M. ; Xiao, J. ; Sheikh, B.N. ; Klöting-Blüher, N. ; Laufs, U. ; Boeckel, J.
Targeting super elongation complex-driven RNA polymerase II elongation reduces plaque vulnerability.Winther, B. ; Schmidt, A. ; Rummler, L. ; Fischer, A. ; Düsing, S. ; Steiner, S. ; Di, X. ; Hirsch, T. ; Scheinert, D. ; Wittig, T.
Long-term outcomes of the “pave-and-crack” technique for severely calcified femoropopliteal chronic total occlusions.Bodner, E. ; Gentz, A. ; Wiencke, K. ; Mehl, N. ; Schlögl, H.
Effectiveness of mobile application-based multimodal behavioral interventions on weight loss in obesity: A systematic Review and meta-analysis.Frendo-Cumbo, S. ; Zareifi, D. ; Bigay, J. ; Dias Araújo, A.R. ; Lapp, A. ; Hansen, M. ; Reindl, T.P. ; Engelmann, B. ; Klingelhuber, F. ; Cordeddu, L. ; Elmastas, M. ; Jalkanen, J. ; Renzi, G. ; Buvry, O. ; Debayle, D. ; Allos, H. ; López Yus, M. ; Weinbrenner, S. ; Schormair, K. ; Jamialahmadi, O. ; Kerr, A.G. ; Romeo, S. ; Rolle-Kampczyk, U. ; von Bergen, M. ; Massier, L. ; Krahmer, N. ; Gautier, R. ; Antonny, B. ; Rydén, M. ; Mejhert, N.
Functional annotation of insulin-responsive genes in human adipocytes reveals PLCXD1 as a lipid storage regulator.Lee, J.Y. ; Zhu, C. ; Boldridge, M.A. ; Stark, R.L. ; Bonilla, G. ; Watari, K. ; Papa, C. ; Xu, L. ; Gonzalez, F. ; Tang, X. ; Dang, K.T. ; Son, K. ; Chetal, K. ; Ibrahim, P. ; Sadreyev, R.I. ; Sheikh, B.N. ; Karin, M. ; Näär, A.M.
A multi-functional oral small molecule targeting energy and lipid metabolism to treat obesity and related metabolic disorders.Luther, M. ; Wittig, T. ; Winther, B. ; Fischer, A. ; Düsing, S. ; Branzan, D. ; Doß, M. ; Schmidt, A. ; Scheinert, D. ; Steiner, S.
Five-year outcomes of endovascular aortoiliac reconstruction in complex lesions: A retrospective single-center study.Mora, P. ; Aroda, V.R. ; Asong, M. ; Blüher, M. ; Carlander, A.L.F. ; Kaltoft, M. ; Vilsen, L.N. ; Rosenstock, J.
Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: A multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.Mora, P. ; Aroda, V.R. ; Asong, M. ; Blüher, M. ; Heftdal, L.D. ; Carlander, A.L.F. ; Vilsen, L.N. ; Rosenstock, J.
Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: A multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.Contact
Leipzig University
University of Leipzig Medical Center
Leipzig Center of Metabolism (LeiCeM)
European Association for the Study of Diabetes (EASD)
German Diabetes Association (Deutsche Diabetes Gesellschaft DDG)
Helmholtz Zentrum für Umweltforschung (UFZ)
Ben-Gurion University of the Negev
Karolinska Institutet
German Center for Child and Adolescent Health (DZKJ)
